Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical Company has announced that Takeda Global R&D Centre, Europe has submitted a marketing authorization application for a prolonged-release formulation of its combination treatment for type 2 diabetes, Competact, to the European Medicines Agency.
Subscribe to our email newsletter
The submission was through the centralized procedure and this new formulation allows once-daily dosing: Competact (pioglitazone HCl and metfomin HCl) is currently available in some European countries as a product to be taken twice-daily.
Takeda is said to be the originator of thiazolidinedione derivatives with the development of Actos (pioglitazone), which directly targets insulin resistance. Metformin acts primarily by reducing the amount of glucose produced by the liver. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels, the company said.
Masaomi Miyamoto, general manager of the pharmaceutical development division of Takeda, said: “This product will provide an additional treatment option for healthcare professionals and patients with type 2 diabetes. Takeda believes this product will further enhance our diabetes franchise in European markets.”